Bioventus vs OrthoPediatrics
BVS and KIDS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BVS and KIDS compare
Bioventus and OrthoPediatrics are about the same size, with market caps of $891M and $820M.
OrthoPediatrics grew revenue faster over the last twelve months (16.1% versus 3.1% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.4% compared with −12.8% at OrthoPediatrics.
Bioventus scores higher on the StockData Score (13 against 11 for OrthoPediatrics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BVS | KIDS |
|---|---|---|
| Size and price | ||
| Market cap | $891M | $820M |
| Share price | $10.60 | $31.41 |
| Change, 1 year | 44.2% | 88.0% |
| Change, 5 years | −15.3% | −46.0% |
| Beta (5Y) | 1.18 | 0.69 |
| Employees | 930 | 602 |
| StockData Score | ||
| Total score | 13 (better) | 11 |
| Valuation score | 4 (better) | 2 |
| Growth score | 2 | 4 (better) |
| Performance score | 5 (better) | 3 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.8× | – |
| P/S | 1.5× (better) | 3.1× |
| P/B | 3.9× | 2.4× (better) |
| EV/EBITDA | 13.9× | – |
| P/FCF | 9.5× (better) | 258× |
| FCF yield | 10.6% (better) | 0.39% |
| Fair value | $17.91 | $34.15 |
| Margin of safety | 40.8% (better) | 8.0% |
| Growth | ||
| Revenue growth (TTM) | 3.1% | 16.1% (better) |
| Revenue growth, 5Y average | 12.1% | 27.2% (better) |
| Profitability | ||
| Gross margin | 68.7% | 73.8% (better) |
| Operating margin | 10.0% (better) | −9.4% |
| Net margin | 9.4% (better) | −12.8% |
| FCF margin | 16.2% (better) | 1.2% |
| Return on equity | 28.0% (better) | −9.8% |
| Return on invested capital | 12.7% (better) | −5.0% |
| Financial health | ||
| Debt / equity | 1.09 | 0.30 (better) |
| Net debt / EBITDA | 2.62 | – |
| Interest coverage | – | −2.7× |
| Current ratio | 1.69 | 4.55 (better) |
| Altman Z-score | 2.07 | 2.90 (better) |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.18% | – |
| Shareholder yield | −0.18% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 71.2% | 64.3% |
| Held by insiders | 29.0% | 30.2% |
| Insider net buying, 12 months | −$181K (better) | −$47.8M |
| Short interest, % of float | 5.1% | 4.1% |
Go deeper
- BVS stock overview
- BVS income statement
- BVS valuation and score
- KIDS stock overview
- KIDS income statement
- KIDS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.